Stocks · News reference
Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its potential additive
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.
Read original at benzingaFiled: 2026-08-06 AccNo: 0001193125-26-338019 Size: 464 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarXenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.15) by 2.63 percent. This is a 3.74 percent decrease over losses of $(1.07) per share
Read original at benzinga